T Cell Immunotherapy for Immune Reconstitution and GVHD Prevention After Allogeneic Hematopoietic Stem Cell Transplantation

被引：1
作者：
Lucarelli B. [1 ]
Merli P. [1 ]
Strocchio L. [1 ]
Cefalo M.G. [1 ]
Brescia L.P. [1 ]
Locatelli F. [1 ,2 ]
机构：
[1] Department of Pediatric Hematology-Oncology, IRCCS, Bambino Gesù Children’s Hospital, Piazza Sant’Onofrio, Rome
[2] Department of Pediatrics, University of Pavia, Pavia
来源：
Current Stem Cell Reports | 2015年 / 1卷 / 4期
基金：
欧盟地平线“2020”;
关键词：
Donor lymphocytes infusions; Hematopoietic stem cell transplantation; Immune reconstitution; Immunotherapy; T cell;
D O I：
10.1007/s40778-015-0027-z
中图分类号：
学科分类号：
摘要：
Many different studies have demonstrated that early recovery of the adaptive immune system after allogeneic hematopoietic stem cell transplantation (HSCT) is predominantly sustained by peripheral expansion of donor-derived, mature lymphocytes transferred with the graft. Different approaches based on the infusion of donor T cells after HSCT have been developed mainly to accelerate immune recovery and to treat/prevent (a) malignancy recurrence, (b) life-threatening infections, and (c) immune-mediated disorders, such as graft-versus-host disease (GVHD). For many years, donor lymphocyte infusion (DLI) has been a widely used approach to prevent and to treat leukemia recurrence, to convert mixed chimerism into complete donor chimerism, and to accelerate immune reconstitution of patients after HSCT. More sophisticated strategies of adoptive infusion of T cell lines/clones capable of mediating a graft-versus-leukemia (GVL) response, while avoiding GVHD occurrence, or specific for the most life-threatening pathogens (e.g., cytomegalovirus, Epstein-Barr virus, and adenovirus) have been envisaged and successfully tested in pilot trials in the early post-transplantation period. Also, ex vivo expanded regulatory T (Treg) cells have been shown to be beneficial for preventing GVHD post-HSCT. In this review, we will focus on DLI as well as more complex cellular therapies that require extensive cell manipulation. © 2015, Springer International Publishing AG.
引用
收藏
页码：206 / 214
页数：8
相关论文
共 100 条
[11]  
Simula M.P., Marktel S., Fozza C., Et al., Response to donor lymphocyte infusions for chronic myeloid leukemia is dose-dependent: the importance of escalating the cell dose to maximize therapeutic efficacy, Leukemia, 21, 5, pp. 943-948, (2007)
[12]  
Schmid C., Labopin M., Nagler A., Et al., Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party, J Clin Oncol, 25, 31, pp. 4938-4945, (2007)
[13]  
Yoshimi A., Bader P., Matthes-Martin S., Et al., Donor leukocyte infusion after hematopoietic stem cell transplantation in patients with juvenile myelomonocytic leukemia, Leukemia, 19, 6, pp. 971-977, (2005)
[14]  
Atra A., Millar B., Shepherd V., Et al., Donor lymphocyte infusion for childhood acute lymphoblastic leukaemia relapsing after bone marrow transplantation, Br J Haematol, 97, 1, pp. 165-168, (1997)
[15]  
De Rosa G., Pezzullo L., Scarpato N., Et al., Donor lymphocyte infusion for post-transplant relapse of Hodgkin's lymphoma, Haematologica, 85, 7, pp. 780-781, (2000)
[16]  
Bloor A.J., Thomson K., Chowdhry N., Et al., High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma, Biol Blood Marrow Transplant, 14, 1, pp. 50-58, (2008)
[17]  
Alyea E., Weller E., Schlossman R., Et al., T-cell-depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect, Blood, 98, 4, pp. 934-939, (2001)
[18]  
Fozza C., Szydlo R.M., Abdel-Rehim M.M., Et al., Factors for graft-versus-host disease after donor lymphocyte infusions with an escalating dose regimen: lack of association with cell dose, Br J Haematol, 136, 6, pp. 833-836, (2007)
[19]  
Guglielmi C., Arcese W., Dazzi F., Et al., Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose, Blood, 100, 2, pp. 397-405, (2002)
[20]  
Tomblyn M., Lazarus H.M., Donor lymphocyte infusions: the long and winding road: how should it be traveled?, Bone Marrow Transplant, 42, 9, pp. 569-579, (2008)
12345678910